SCHEMBL1765865

SCHEMBL1765865

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccc(OCC(=O)O)c(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.62
PPARD Q03181 5/20 0.62
PPARG P37231 4/20 0.62
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
LPAR2 Q9HBW0 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
HTT P42858 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765936 0.94 PPARD (0.68) PPARAPPARDPPARGTDP1TSHR
SCHEMBL12732439 0.93 PPARA (0.54) PPARAPPARDPPARGTDP1TSHR
SCHEMBL24742416 0.90 PPARA (0.50) PPARAPPARDPPARGTDP1TSHR
SCHEMBL30004652 0.90 PPARA (0.50) PPARAPPARDPPARGTDP1TSHR
SCHEMBL2467711 0.89 PPARG (0.56) PPARAPPARDPPARGTDP1TSHR
SCHEMBL4754218 0.88 PPARA (0.49) PPARAPPARDPPARGTSHRSMN1; SMN2
SCHEMBL2460899 0.87 PPARD (0.59) PPARAPPARDPPARGPTGDR2LPAR2
SCHEMBL1765978 0.87 PPARA (0.61) PPARAPPARDPPARGTSHRSMN1; SMN2
SCHEMBL4754216 0.86 PPARA (0.48) PPARAPPARDPPARGTSHRSMN1; SMN2
SCHEMBL12732396 0.86 PPARG (0.57) PPARAPPARDPPARGTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190255022-A1 WOUND-HEALING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2019-08-22 US claimed
EP-3456327-A1 WOUND-HEALING AGENT Nippon Chemiphar Co., Ltd. (JP) 2019-03-20 EP claimed
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US claimed
US-20190255022-A1 WOUND-HEALING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2019-08-22 US disclosed
EP-3456327-A1 WOUND-HEALING AGENT Nippon Chemiphar Co., Ltd. (JP) 2019-03-20 EP disclosed
EP-2464349-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES Cerenis Therapeutics S.A. (FR) 2012-06-20 EP disclosed
EP-1424330-B1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO (JP) 2011-09-28 EP disclosed
WO-2011020001-A9 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-05-26 WO disclosed
WO-2011020001-A2 USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES CERENIS THERAPEUTICS S.A. (FR) 2011-02-17 WO disclosed
US-7652045-B2 e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) NIPPON CHEMIPHAR, CO., LTD. (JP) 2010-01-26 US disclosed
US-7648999-B2 Activator for peroxisome proliferator-activated receptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2010-01-19 US disclosed
WO-2008154023-A1 NOVEL USES OF PPAR DELTA AGONISTS CERENIS THERAPEUTICS S.A. (FR) 2008-12-18 WO disclosed
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta SAKUMA SHOGO 2008-01-10 US disclosed
US-7265137-B2 Activator of peroxisome proliferator-activated re-ceptor δ NIPPON CHEMIPHAR CO., LTD. (JP) 2007-09-04 US disclosed
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2005-03-10 US disclosed
EP-1424330-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA NIPPON CHEMIPHAR CO., LTD. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009525-A1 Activator of peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885
US-20190255022-A1 WOUND-HEALING AGENT PPARG, PPARA, PPARD PPARA 2/4885PPARD 3/4885PPARG 1/4885
US-20080009631-A1 Activator for peroxisome proliferator-activated receptor delta PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885
US-20050054674-A1 Activator of peroxisome proliferator-activated receptor PPARG, PPARD, PPARA PPARA 3/4885PPARD 2/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.